A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle; Scott C. Bell; Michael W. Konstan; Susanna A. McColley; Steven M. Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish Patel; David M. Rodman

doi:10.1016/s2213-2600(14)70132-8

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

著者: Michael Boyle, Scott C. Bell, Michael W. Konstan, Susanna A. McColley, Steven M. Rowe, Ernst Rietschel, Xiaohong Huang, David Waltz, Naimish Patel, David M. Rodman - The Lancet 2014 被引用: 442

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial | Litlas